Document:

EX-10.2

  Exhibit 10.2

   

  Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark [***].

  First Amendment to COLLABORATION AND LICENSE AGREEMENT

  between

  F. Hoffmann-La Roche Ltd
Grenzacherstrasse 124
4070 Basel
Switzerland
(hereinafter called Roche)

   

  Genentech, Inc.

  1 DNA Way

  South San Francisco, California 94080

  United States of America

  (hereinafter called Genentech)

   

  Genentech and Roche, together, “Licensee”

   

  and

  Relay Therapeutics, Inc..
399 Binney Street, 2nd Floor 
Cambridge, Massachusetts 02139
United States of America
(hereinafter called Relay)

   

  (both individually a “Party” and collectively the “Parties”)

   

   

  Whereas Licensee and Relay entered into an agreement (hereinafter called Collaboration and License Agreement) with the effective date December 11, 2020;

   

  Whereas Licensee and Relay now wish to amend certain provisions of the Collaboration and License Agreement; 

  Now therefore the Parties agree as follows:

   

  

  		2

  1Miscellaneous

  1.1The Collaboration and License Agreement, along with this First Amendment, constitutes the entire agreement between the Parties and supersedes all previous oral and written communications between the Parties with respect to the subject matter thereof. 

  1.2All terms of the Collaboration and License Agreement not varied by inclusion in this First Amendment remain in full force and effect.

  1.3The singular includes the plural and vice versa.

  1.4References in this First Amendment to articles, sections, appendixes or schedules are to articles, sections, appendixes or schedules (as the case may be) of this First Amendment unless otherwise specified.

  1.5The terms ‘including’, ‘exemplified by’, e.g.’ or ‘such as’ will be deemed to be followed by the words ‘but not limited to’.

  2Article 1 (DEFINITIONS) 

  2.1All capitalized terms not defined in this First Amendment will have the meanings given to them in the Collaboration and License Agreement. 

  3Article 15 (INDEMNIFICATION; INSURANCE)

  3.1Section 15.4.2 of the Collaboration Agreement shall be deleted in its entirety and replaced by the following: 

  15.4.2	All insurance maintained pursuant to this Section 15.4 will be underwritten by companies with an AM best rating of at least A-VII. Each Party will provide the other Party with written evidence of such insurance upon request. Each Party will provide the other Party written notice of at least [***] days prior to the cancellation, non-renewal or material change in such insurance. Each Party shall name the other Party as additional insured under its commercial general liability insurance policy.

  4 eSignature[s]

  4.1The Parties agree that in order to fulfil the written form requirement of this First Agreement, as alternative to handwritten signatures on a hardcopy, electronic signatures (“eSignature[s]”) of duly authorized representatives of the Parties may be used. eSignature shall mean a signature that consists of one or more letters, characters, numbers or other symbols in digital form incorporated in, attached to or associated with the electronic document, that

  (a)   is unique to the person executing the signature

  (b)   the technology or process used to make the signature is under the sole control of the person making the signature

  (c)   the technology or process can be used to identify the person using the technology or process, and

  (d)   the electronic signature can be linked with an electronic document in such a way that it can be used to determine whether the electronic document has been changed since the electronic signature was incorporated in, attached to or associated with the electronic document.

   

  

  		3

   

   

   

  [Signatures on next page]

   

   

  

  		4

  This First Amendment will come into force on the date it has been signed by both Parties.

   

  		
	F. Hoffmann-La Roche Ltd

	By: /s/ Urs Schleuniger 
Name: Urs Schleuniger
Title: Global Head Alliance & Asset Management
Date: 27-Jan-2022
	By: /s/ Barbara Schroeder de Castro Lopes
Name: Barbara Schroeder de Castro Lopes 
Title: Authorized Signatory
Date: 02-Feb-2022

	 
Genentech, Inc. 

	By: /s/  Beth Odeh-Frikert 
Name: Beth Odeh-Frikert 
Title: Head Alliance & Asset Management, SSF 
Date: 27-Jan-2022

   

   

  	
	Relay Therapeutics, Inc..

	By: /s/ Brian Adams
Name: Brian Adams
Title: Chief Legal Officer
Date: 02-Feb-2022Document

February 23, 2022                                    Exhibit 10.1
Colleen Healy

Dear Colleen:
I am excited to offer you full-time employment with SailPoint Technologies, Inc. (“SailPoint”), with the expectation that you will subsequently be appointed as Chief Financial Officer of SailPoint and SailPoint Technologies Holdings, Inc. on or around March 16, 2022. This letter confirms the details of SailPoint’s offer of employment, subject to the approval of the Board of Directors of SailPoint Technologies Holdings, Inc. (the “Board”), with an anticipated start date of February 24, 2022.  
1.Compensation. Your annual base salary will be $425,000; paid semi-monthly (typically on the 15th and last day of each month) consistent with our standard payroll procedures and reduced by payroll deductions and all required withholdings.
You will also be eligible for a bonus of up to 60% of your annual base salary based on your continued employment and achievement of corporate goals as set forth by the Compensation Committee of the Board and subject to the terms and conditions of our corporate bonus plan.  
In addition, SailPoint will provide you with a one-time sign-on bonus of $100,000, less applicable withholdings and deductions (the “Sign-On Bonus”), to be paid within thirty (30) days following your start date. In the event that you resign or your employment is terminated for Cause (as defined in the SailPoint Technologies Holdings, Inc. Severance Pay Plan) before the first anniversary of your start date, you will be required to repay SailPoint 100% of the Sign-On Bonus (the “Repayment Amount”) within thirty (30) days of your termination date. Your signature below authorizes SailPoint to deduct the Repayment Amount from any monies owed to you, including amounts from any wages, commissions, bonuses, or expense reimbursements, upon such resignation or termination, to the extent permitted by law.
2.Equity Awards. Subject to approval by the Board, you will be granted an award of restricted stock units determined by dividing $5,000,000 by the 30 trading day average closing price of the common stock of SailPoint Technologies Holdings, Inc. (“Common Stock”) on the date that you begin employment (the “Hire Date RSUs”).  The Hire Date RSUs represent the right to receive shares of Common Stock and will vest and be settled in 13 installments  25% approximately one year from the date of grant and 6.25% per quarter over the following 12 quarters thereafter.  Vest dates are set each quarter as follows: February 28, May 28, August 28 and November 28.  
All vesting of the Hire Date RSUs is contingent upon your continued employment with SailPoint; provided, however, if you incur a “separation from service” (within the meaning of Treasury Regulation § 1.409A-1(h)) due to a termination of your employment by SailPoint without “Cause” or due to your resignation from employment with SailPoint due to “Good Reason,” any unvested Hire Date RSUs that would have become vested and nonforfeitable during the two year period beginning on the date of your separation from service had you continued employment, will become vested and nonforfeitable upon such 
SailPoint Technologies, Inc.   |   www.sailpoint.com
    11120 Four Points Drive, Suite 100   |   Austin, Texas 78726   |   T  512.346.2000    

termination and settleable pursuant to the terms of your Hire RSU award agreement. The RSUs are subject to the terms and conditions of the SailPoint’s 2017 Long Term Incentive Plan (the “LTIP”) and the award agreements evidencing such awards.  “Cause” and “Good Reason” will have the meanings provided in, and will be determined pursuant to, the SailPoint Technologies Holdings, Inc. Severance Pay Plan (the “Severance Plan”).  For the sake of clarity, in the event of a Change in Control (as defined in the LTIP) you will receive the enhanced vesting protection with respect to your Hire Date RSUs contemplated by and pursuant to the Severance Plan rather than the vesting protection set forth in this paragraph.
3.Executive Severance. So long as you are serving in the capacity of the Chief Financial Officer (or other similarly senior executive position), you will be eligible for participation in the Severance Plan, subject to the approval of both the Chief Executive Officer and the Compensation Committee of the Board and pursuant to the terms and conditions of the plan.  
4.Benefits. You will be eligible to participate in a comprehensive package of employee benefits, which includes medical, dental, vision, group life insurance and a 401(k) plan. 
5.Work Authorization. In compliance with Federal Immigration law, this offer of employment is contingent upon your ability to provide proof of eligibility and right to work in the United States. This documentation must be provided within three business days of the effective date of your employment.
6.Background Check. As a condition of accepting this offer of employment, you may be required to submit to a background screening. Unsatisfactory results from, refusal to cooperate with, or any attempt to affect the results of this check may result in termination of employment.
7.Proprietary Information, Inventions Assignment and Protective Covenants Agreement. As a condition of accepting this offer of employment, you will be required to complete, sign and return SailPoint’s Proprietary Information, Inventions Assignment and Protective Covenants Agreement.
8.General. This offer letter, when signed by you, and the Proprietary Information, Inventions Assignment and Protective Covenants Agreement set forth the terms of your employment with SailPoint and supersedes all prior terms or discussions. In particular, by signing this offer letter, you hereby agree that the Consulting Agreement entered into between you and SailPoint on or around January 19, 2022 will terminate immediately prior to your commencement of employment. This letter agreement can only be amended in writing, signed by you and an authorized officer of SailPoint.
Your employment with SailPoint is at will and may be terminated by you or by SailPoint at any time and for any reason, with or without cause. No statement on this letter, any SailPoint booklet, brochure, guideline, manual, policy or plan should be construed as creating an employment contract for any specific duration.
If these terms are agreeable, please indicate your acceptance by signing this letter in the space provided below and returning it to me.
Colleen, we look forward to welcoming you onto the SailPoint team. We are committed to continuing to build a great company. With your help, I am confident we will succeed.
2

Sincerely,

/s/ Mark McClain                
Mark McClain
CEO & Founder

AGREED AND ACCEPTED:

/s/ Colleen Healy    
Colleen Healy

February 23, 2022    
Date
3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00344-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00344-of-00352.parquet"}]]